Cerba Research Expands Global Spectral Flow Cytometry Capabilities with Additional Cytek Aurora™ Evo Instruments

We are expanding our global spectral flow cytometry footprint with additional Cytek Aurora™ Evo installations, further strengthening our global spectral flow cytometry laboratories across North America, Europe, Asia, and Australia.

The addition of a second Cytek Aurora™ Evo in both the United States and Europe enhances instrument harmonization and operational redundancy in these regions. In the Asia Pacific region, our partner laboratory in Australia continues to support our established capabilities with redundant spectral flow cytometers. Complementing this footprint, our partner laboratory in China, Teddy Laboratories, has added its first spectral flow cytometer, marking an important expansion of our spectral flow expertise and capacity in Asia.

Together, this network gives sponsors access to consistent, highly reproducible, high-dimensional multi-color data and greater operational flexibility across every major region we serve, particularly for studies using fresh blood and bone marrow aspirate samples.

This investment responds directly to growing sponsor demand for globally harmonized spectral flow cytometry. As more cell and gene therapy, immunonology, and oncology studies incorporate high-dimensional immune profiling.

“Having matching systems in place across some of our major regions significantly strengthens our global offering,” said Nithianandan Selliah, Global Director of Flow Cytometry at Cerba Research. “It removes a key operational risk for studies using fresh samples and gives sponsors real confidence that we can deliver consistent, high-quality data no matter where their trial is running.”

This expansion also broadens the range of spectral flow cytometry panels we can run, giving sponsors more flexibility in study design and helping them generate deeper immunological insights without compromising operational reliability.

These installations form part of our wider investment in advanced flow cytometry. Combined with our recent partnership with Ozette Technologies, we continue to strengthen our end-to-end single-cell analysis offering, pairing high-dimensional spectral flow cytometry with AI-powered analytics to deliver richer insights from complex immune datasets.

As harmonization activities continue across our network, this expanded infrastructure positions us to support a growing number of global clinical trials that require standardized spectral flow cytometry workflows and reliable access to advanced immune profiling expertise.

Find out how our expanded spectral flow cytometry network can support your next study.